JP2015522573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522573A5 JP2015522573A5 JP2015519000A JP2015519000A JP2015522573A5 JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5 JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- composition according
- composition
- glp
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 8
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000036186 satiety Effects 0.000 claims 2
- 235000019627 satiety Nutrition 0.000 claims 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical group CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950011186 semaglutide Drugs 0.000 claims 1
- 108010060325 semaglutide Proteins 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535 | 2012-07-01 | ||
| EP12174535.0 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US61/694,837 | 2012-08-30 | ||
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| EP12186781 | 2012-10-01 | ||
| EP12186781.6 | 2012-10-01 | ||
| US61/708,162 | 2012-10-01 | ||
| PCT/EP2013/063004 WO2014005858A1 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522573A JP2015522573A (ja) | 2015-08-06 |
| JP2015522573A5 true JP2015522573A5 (enExample) | 2016-03-10 |
| JP6059802B2 JP6059802B2 (ja) | 2017-01-11 |
Family
ID=65858459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519000A Active JP6059802B2 (ja) | 2012-07-01 | 2013-06-21 | 長時間作用型ｇｌｐ−１ペプチドの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9764003B2 (enExample) |
| EP (3) | EP2866825B1 (enExample) |
| JP (1) | JP6059802B2 (enExample) |
| AU (3) | AU2013286177B2 (enExample) |
| BR (1) | BR112014032938A2 (enExample) |
| CA (1) | CA2877056A1 (enExample) |
| DK (1) | DK2866825T3 (enExample) |
| ES (2) | ES3041720T3 (enExample) |
| HR (2) | HRP20251088T1 (enExample) |
| HU (1) | HUE049152T2 (enExample) |
| MX (3) | MX366405B (enExample) |
| PL (2) | PL3689365T3 (enExample) |
| PT (1) | PT2866825T (enExample) |
| RS (2) | RS60432B1 (enExample) |
| RU (2) | RU2657573C2 (enExample) |
| SI (1) | SI2866825T1 (enExample) |
| WO (1) | WO2014005858A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60321B1 (sr) | 2010-12-16 | 2020-07-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline |
| DK2696687T3 (en) | 2011-04-12 | 2017-02-06 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
| PL2827885T3 (pl) | 2012-03-22 | 2019-01-31 | Novo Nordisk A/S | Kompozycje peptydów GLP-1 i ich otrzymywanie |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| ES3041720T3 (en) | 2012-07-01 | 2025-11-14 | Novo Nordisk As | Use of long-acting glp-1 peptides |
| KR20210086717A (ko) | 2013-05-02 | 2021-07-08 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| US10543843B2 (en) * | 2014-10-16 | 2020-01-28 | Yanmar Co., Ltd. | Work vehicle |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| MX2020001525A (es) | 2017-08-24 | 2020-03-20 | Novo Nordisk As | Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos. |
| IL322969A (en) | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical therapy |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| CN111683676B (zh) | 2018-02-02 | 2024-06-18 | 诺和诺德股份有限公司 | 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物 |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| US20210162013A1 (en) * | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| AU2020229349A1 (en) * | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
| MX2022004779A (es) * | 2019-11-06 | 2022-06-14 | Novo Nordisk As | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. |
| CN119060161A (zh) * | 2019-12-30 | 2024-12-03 | 甘李药业股份有限公司 | 长效glp-1化合物 |
| IL294520A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | Pharmaceutical formulations |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| EP4359074A4 (en) * | 2021-06-24 | 2025-06-04 | Gila Therapeutics, Inc. | METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| AU2022349020A1 (en) | 2021-09-27 | 2024-05-09 | Terns Pharmaceuticals, Inc. | Benzimidazole carboxylic acids as glp-1r agonists |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| IL312672A (en) | 2021-11-10 | 2024-07-01 | I2O Therapeutics Inc | Ionic liquid compositions |
| CN115850438B (zh) * | 2021-12-28 | 2023-05-12 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| US20230374096A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| KR20250141711A (ko) | 2022-12-30 | 2025-09-29 | 알지파마 에이에스 | 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법 |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
| WO2025024455A1 (en) | 2023-07-24 | 2025-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivery of therapeutic peptides |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| CZ300837B6 (cs) | 1996-08-30 | 2009-08-26 | Novo Nordisk A/S | Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití |
| WO2003002136A2 (en) | 2001-06-28 | 2003-01-09 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| CN1882356B (zh) | 2003-11-20 | 2015-02-25 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| CN106137952B (zh) | 2004-11-12 | 2020-11-17 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| BRPI0709964A2 (pt) | 2006-04-14 | 2011-08-02 | Mannkind Corp | formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1) |
| CA2677852A1 (en) | 2007-03-20 | 2008-09-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| JP5476304B2 (ja) | 2007-09-05 | 2014-04-23 | ノボ・ノルデイスク・エー／エス | グルカゴン様ペプチド−１誘導体及びそれらの医薬用途 |
| EP2190873B1 (en) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| JP2012511586A (ja) | 2008-12-10 | 2012-05-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 医薬組成物 |
| CA2752437C (en) * | 2009-02-13 | 2017-07-11 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
| WO2011080103A1 (en) * | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| RS60321B1 (sr) | 2010-12-16 | 2020-07-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| CN103906528A (zh) * | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
| ES3041720T3 (en) | 2012-07-01 | 2025-11-14 | Novo Nordisk As | Use of long-acting glp-1 peptides |
-
2013
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522573A5 (enExample) | ||
| MX2022004041A (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| GB2491328A (en) | Immediate/delayed drug delivery | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| MX339614B (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2012193216A5 (enExample) | ||
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| AU2018256619A1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| AU2012334804A8 (en) | Modulators of C3a receptors | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| WO2011119649A3 (en) | Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs | |
| WO2016072692A3 (ko) | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 | |
| MX2018005345A (es) | Composiciones farmaceuticas de dimetil fumarato. | |
| JP2018043942A5 (enExample) | ||
| Sheehy | Ketamine/morphine | |
| WO2014071339A3 (en) | Bremelanotide therapy for female sexual dysfunction | |
| Carman | Ferric carboxymaltose | |
| JP2017514820A5 (enExample) |